Jiangsu Hengrui gets conditional approval for new cancer drug
Photo: AInvest / iStock
BEIJING, 5 September (BelTA — China Daily) — The Chinese company Jiangsu
Hengrui Pharmaceuticals said in a statement that it has received
conditional approval from the National Medical Products Administration
for its new cancer drug, Zeprumetostat.
The treatment has been
cleared for use by adult patients with relapsed or refractory peripheral
T-cell lymphoma who have already received at least one systemic
therapy. R/R PTCL is a rare and aggressive blood cancer with limited
treatment options.
Zeprumetostat is China’s first domestically
developed EZH2 inhibitor. EZH2 is an enzyme tied to cancer cell growth,
and drugs targeting it are seen as a promising approach in oncology.
Hengrui describes its product as a selective, oral therapy designed to
offer new hope for patients.
Under conditional approval, the
medicine can be marketed while the company continues to supply
longer-term clinical data on safety and effectiveness.
